Vanguard Group Inc. Acquires 3,438 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

Vanguard Group Inc. lifted its holdings in Kodiak Sciences Inc. (NASDAQ:KOD) by 0.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,633,016 shares of the company’s stock after purchasing an additional 3,438 shares during the quarter. Vanguard Group Inc.’s holdings in Kodiak Sciences were worth $2,939,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Point72 Middle East FZE bought a new stake in shares of Kodiak Sciences in the fourth quarter worth $27,000. UBS Group AG increased its holdings in Kodiak Sciences by 26,200.0% during the third quarter. UBS Group AG now owns 6,575 shares of the company’s stock worth $51,000 after buying an additional 6,550 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in Kodiak Sciences during the third quarter worth $55,000. Royal Bank of Canada increased its holdings in Kodiak Sciences by 89.0% during the third quarter. Royal Bank of Canada now owns 7,592 shares of the company’s stock worth $59,000 after buying an additional 3,575 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its holdings in Kodiak Sciences by 64.4% during the third quarter. Ensign Peak Advisors Inc now owns 9,570 shares of the company’s stock worth $74,000 after buying an additional 3,750 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on KOD shares. Barclays boosted their target price on shares of Kodiak Sciences from $2.00 to $3.00 and gave the stock an “underweight” rating in a report on Monday, April 1st. UBS Group boosted their target price on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a “neutral” rating in a report on Thursday, April 4th. Three analysts have rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Kodiak Sciences presently has a consensus rating of “Hold” and an average price target of $5.50.

Kodiak Sciences Price Performance

NASDAQ:KOD opened at $3.87 on Tuesday. Kodiak Sciences Inc. has a one year low of $1.37 and a one year high of $9.80. The company has a market cap of $203.21 million, a P/E ratio of -0.78 and a beta of 2.15. The firm’s fifty day moving average price is $5.39 and its two-hundred day moving average price is $3.59.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.